vs
Side-by-side financial comparison of Day One Biopharmaceuticals, Inc. (DAWN) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.
Day One Biopharmaceuticals, Inc. is the larger business by last-quarter revenue ($39.8M vs $20.3M, roughly 2.0× Ispire Technology Inc.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -49.6%, a 17.0% gap on every dollar of revenue. On growth, Ispire Technology Inc. posted the faster year-over-year revenue change (-51.5% vs -57.6%).
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.
DAWN vs ISPR — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $39.8M | $20.3M |
| Net Profit | $-19.7M | $-6.6M |
| Gross Margin | — | 17.1% |
| Operating Margin | -60.9% | -33.9% |
| Net Margin | -49.6% | -32.5% |
| Revenue YoY | -57.6% | -51.5% |
| Net Profit YoY | -153.3% | 17.4% |
| EPS (diluted) | $-0.19 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.3M | ||
| Q3 25 | $39.8M | $30.4M | ||
| Q2 25 | $33.9M | $20.1M | ||
| Q1 25 | $30.8M | $26.2M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | $93.8M | $39.3M | ||
| Q2 24 | — | $37.3M | ||
| Q1 24 | $0 | $30.0M |
| Q4 25 | — | $-6.6M | ||
| Q3 25 | $-19.7M | $-3.3M | ||
| Q2 25 | $-30.3M | $-14.8M | ||
| Q1 25 | $-36.0M | $-10.9M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | $37.0M | $-5.6M | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | $-62.4M | $-5.9M |
| Q4 25 | — | 17.1% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 18.2% | ||
| Q4 24 | — | 18.5% | ||
| Q3 24 | — | 19.5% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | — | 20.4% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | -60.9% | -8.9% | ||
| Q2 25 | -103.1% | -72.7% | ||
| Q1 25 | -133.5% | -40.4% | ||
| Q4 24 | — | -17.6% | ||
| Q3 24 | 31.6% | -13.4% | ||
| Q2 24 | — | -9.2% | ||
| Q1 24 | — | -18.8% |
| Q4 25 | — | -32.5% | ||
| Q3 25 | -49.6% | -10.7% | ||
| Q2 25 | -89.4% | -73.4% | ||
| Q1 25 | -117.0% | -41.5% | ||
| Q4 24 | — | -19.1% | ||
| Q3 24 | 39.5% | -14.2% | ||
| Q2 24 | — | -9.4% | ||
| Q1 24 | — | -19.7% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | $-0.19 | $-0.06 | ||
| Q2 25 | $-0.29 | $-0.26 | ||
| Q1 25 | $-0.35 | $-0.19 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | $0.38 | $-0.10 | ||
| Q2 24 | — | $-0.07 | ||
| Q1 24 | $-0.72 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $451.6M | $17.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $450.9M | $-7.7M |
| Total Assets | $513.8M | $84.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.6M | ||
| Q3 25 | $451.6M | $22.7M | ||
| Q2 25 | $453.1M | $24.4M | ||
| Q1 25 | $473.0M | $23.5M | ||
| Q4 24 | — | $34.4M | ||
| Q3 24 | $558.4M | $37.7M | ||
| Q2 24 | — | $35.1M | ||
| Q1 24 | $317.9M | $39.5M |
| Q4 25 | — | $-7.7M | ||
| Q3 25 | $450.9M | $-1.8M | ||
| Q2 25 | $460.8M | $604.7K | ||
| Q1 25 | $479.5M | $14.8M | ||
| Q4 24 | — | $24.2M | ||
| Q3 24 | $555.5M | $30.7M | ||
| Q2 24 | — | $34.5M | ||
| Q1 24 | $296.8M | $35.9M |
| Q4 25 | — | $84.4M | ||
| Q3 25 | $513.8M | $96.4M | ||
| Q2 25 | $519.0M | $102.2M | ||
| Q1 25 | $534.4M | $115.7M | ||
| Q4 24 | — | $132.0M | ||
| Q3 24 | $600.8M | $129.0M | ||
| Q2 24 | — | $122.6M | ||
| Q1 24 | $326.6M | $108.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $-4.0M |
| Free Cash FlowOCF − Capex | — | $-4.0M |
| FCF MarginFCF / Revenue | — | -19.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.0M | ||
| Q3 25 | $-5.8M | $-1.2M | ||
| Q2 25 | $-24.8M | $4.7M | ||
| Q1 25 | $-59.0M | $-12.5M | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | $50.8M | $3.6M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | $-49.7M | $3.4M |
| Q4 25 | — | $-4.0M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-24.8M | $3.7M | ||
| Q1 25 | $-59.3M | $-12.7M | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | $50.0M | $3.3M | ||
| Q2 24 | — | $-2.2M | ||
| Q1 24 | — | $3.3M |
| Q4 25 | — | -19.9% | ||
| Q3 25 | — | -3.9% | ||
| Q2 25 | -73.2% | 18.6% | ||
| Q1 25 | -192.8% | -48.4% | ||
| Q4 24 | — | -7.7% | ||
| Q3 24 | 53.4% | 8.5% | ||
| Q2 24 | — | -5.9% | ||
| Q1 24 | — | 10.9% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 1.0% | 0.7% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.8% | 0.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
ISPR
Segment breakdown not available.
